HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma

Sohn, Woon Mok; Paik, Yong–Han; Kim, Jong Man; Kwon, Choon Hyuck David; Cho, Ju Yeon; Gwak, Geum‐Youn; Choi, Moon Seok; Lee, Joon Hyeok; Koh, Kwang Cheol; Paik, Seung Woon; Yoo, Byung Chul

doi:10.1245/s10434-014-3621-x

Cited by 95 publications

(102 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The multinodular-diffuse type of recurrence is early in almost 90 % of patients and is rarely treatable and the unsatisfactory long-term survival ascribed to the early when compared with the late recurrences [24]. Other previous studies also analyzed the prognostic results using cutoff of 2 years in HCC [26][27][28]. In total, there were 330 patients with recurrence including 250 early recurrent and 80 late recurrent patients in the present study.…”

Section: Discussionmentioning

confidence: 84%

MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

The MET and RON receptors are tyrosine kinases that form a non-covalent complex on the cell surface that functions in several steps of tumor progression. The purpose of this study was to determine the clinical significance of MET and RON expression on long-term survival and recurrence after curative resection in a large cohort of hepatocellular carcinoma (HCC) patients. We performed immunohistochemical analyses on microarrays of the tumors using antibodies against MET and RON. We evaluated the prognostic value of biomarker expression using Cox regression and the Kaplan-Meier method in 490 HCC patients. MET-positive patients had higher overall recurrence rates than MET-negative patients (P = 0.041); however, MET positivity was not associated with overall survival (OS) (P = .249). RON was not associated with overall recurrence rates and OS. MET was independently associated with late but not early phase recurrence. Particularly, the prognostic significance of MET is limited in early stage disease. MET+/RON+ patients had higher overall recurrence rates than those with the other expression patterns (P = 0.071), although the result did not reach statistical significance. Immunohistological activation of MET expression has no prognostic significance for OS in patients with HCC. However, MET positivity was correlated with late recurrence after HCC resection in early stage disease.

show abstract

Section: Discussionmentioning

confidence: 84%

MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In contrast, late recurrence is usually as a result of new primary HCC from de novo carcinogenesis arising from a premalignant liver. Therefore, the latter is more related to the characteristics of the remnant liver, including the presence of cirrhosis, inflammatory activity, and viral load [47,48] . The fibrotic burden and the presence of cirrhosis may increase the chance of recurrence and reduce disease-free and overall survival after resection [49] .…”

Section: Antiviral Therapy For Hcc Patients Undergoing Surgical Resecmentioning

confidence: 99%

The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma

Fung¹,

Chok²

2017

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) in places where chronic hepatitis B infection is endemic. Oral nucleos(t)ide analog (NA) therapy can reduce the risk of HCC, but cannot completely prevent its development. For HBV-related HCCs, viral inhibition by NAs can preserve or improve liver function, thereby increasing the chance of therapeutic intervention. After surgical resection, NAs can prevent reactivation of HBV, and also reduce the chance of de novo development of HCC in the remnant liver. For those who undergo liver transplantation, NAs are essential to prevent reactivation and graft hepatitis, but is not likely to prevent HCC recurrence, which is due to metastatic disease. The role of NAs for non-curable advanced HCC is less well defined. These include patients undergoing locoregional therapy, chemotherapy, or palliation. Although antiviral therapy can preserve liver function, which may be compromised by HBV, it is unable to prevent disease progression from HCC. At the time of HCC diagnosis, most patients will already be receiving NAs, and these patients should be maintained on therapy. For patients not on antiviral therapy at the time of HCC diagnosis, the decision to commence therapy is often determined by the stage of HCC and life expectancy. Patients undergoing curative therapy, or locoregional therapy/chemotherapy with reasonable life expectancy, should be commenced on antiviral therapy. Key words:Antiviral therapy, hepatitis B virus, hepatocellular carcinoma ABSTRACTArticle history:

show abstract

“…Early recurrence is predominantly due to intrahepatic metastasis arising from the primary tumor, while late recurrence results primarily from de novo (multicentric) metastasis. Risk factors of early recurrence are associated with the HCC itself and include tumor size and number, tumor differentiation, vascular invasion, tumor capsule and resection margin (4,5). By contrast, risk factors of late recurrence are associated with remnant liver tissue and include high viral load and hepatic inflammatory activity (4,5).…”

Section: Risk Factors Of Hcc Recurrencementioning

confidence: 99%

Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy

Gong

Zhong

Xiang

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated mortalities, and its prevalence is expected to increase in future decades. Hepatitis B virus (HBV) infection is the leading cause of HCC. Although hepatectomy is the preferred curative treatment for HCC, tumor recurrence is common, which is the most frequent cause of mortality in patients with HCC. HCC recurrence may originate from the primary tumor or be associated with remnant liver tissue, and include high viral load and hepatic inflammatory activity. Adjuvant transarterial chemoembolization and postoperative nucleos(t)ide analogs therapy are the two corresponding therapies. Following systematic searching of the PubMed database, the indications for adjuvant transarterial chemoembolization and nucleos(t)ide analog therapies for HBV-related HCC after hepatectomy were acquired. Additionally, the feasibility of combining these two therapies were also reviewed.

show abstract

HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma

Abstract: The HBV DNA levels were associated with early recurrence, whereas HBsAg levels were associated with late recurrence after curative resection in HBV-related HCC.

Cited by 95 publications

References 24 publications

MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma

MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma

The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma

Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy

Contact Info

Product

Resources

About